Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.

Sudhir GuptaJames DeAngeloIsaac MelamedJolan E WalterAi-Lan KobayashiTracy BridgesJ Wesley SublettJonathan A BernsteinAlan KoterbaMichael ManningJoanna MalteseSonja HoellerEva Turpel-KantorHuub KreuwelRoger H Kobayashi

Published in: Journal of clinical immunology (2023)

SCIG 16.5% (Cutaquig®), infusions are efficacious, safe, and well tolerated with reduced infusion time, fewer infusion sites, and reduced frequency. Further, the majority of patients found the new infusion regimens to be better or somewhat better than their previous regimens.

Keyphrases

low dose
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
patient reported outcomes
open label
peritoneal dialysis
randomized controlled trial
clinical trial
patient reported